



**PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)**

COPHy Global 2022 Virtual Program by Section

HALL A

BIG CONTROVERSIES IN RETINA IN 2022

Friday, June 24, 2022		Hall A
11:00-12:30	<b>Big Controversies in Retina in 2022</b>	
Chairs:	<b><u>Baruch Kuppermann</u>, USA; <u>Anat Loewenstein</u>, Israel</b>	
11:00-11:10	<b>Open Remarks: <u>Baruch Kuppermann</u>, USA; <u>Anat Loewenstein</u>, Israel</b>	
11:10-11:30	<b>Key note consensus gaps</b>	
11:10-11:25	<b>Dealing with Controversies in Clinical Practice: <i>How To Manage Patients when Clinical Trials Show One Outcome is Not Superior to Another</i></b> <b><u>Neil Bressler</u>, USA</b>	
11:25-11:30	Q&A	
11:30-12:00	<b>Debate 1: AI will improve retinal disease monitoring and management in less than 5 years</b>	
11:30-11:40	Yes: <b><u>Pearse Keane</u>, UK</b>	
11:40-11:50	No: <b><u>Francesco Bandello</u>, Italy</b>	
11:50-12:00	Discussion	
12:00-12:30	<b>Debate 2: Complement inhibition will be an important part of our armamentarium in the management of geographic atrophy</b>	
12:00-12:10	Yes: <b><u>Philip J. Rosenfeld</u>, USA</b>	
12:10-12:20	No: <b><u>Jayakrishna Ambati</u>, USA</b>	
12:20-12:30	Discussion	
12:30-13:00	<b><i>Visit Companies Information Corner and ePosters</i></b>	



**PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)**

**MEDICAL RETINA 1 | Neovascular (“Wet”) AMD Management**

<b>Friday, June 24, 2022</b>		<b>Hall A</b>
<b>13:00-14:30</b>	<b>MEDICAL RETINA 1   Neovascular (“Wet”) AMD Management</b>	
Chairs:	<b><u>Jean-Francois Korobelnik</u></b> , France; <b><u>Michaella Goldstein</u></b> , Israel	
<b>13:00-13:30</b>	<b>Debate 1: Is there a role for brolucizumab in the treatment of retinal disease.</b>	
13:00-13:10	Yes: <b><u>Giuseppe Querques</u></b> , Italy	
13:10-13:20	No: <b><u>Sharon Fekrat</u></b> , USA	
13:20-13:30	Discussion	
<b>13:30-14:00</b>	<b>Debate 2: Higher doses of existing intravitreal drugs can be beneficial in the management of nAMD</b>	
13:30-13:40	Yes: <b><u>David M. Brown</u></b> , USA	
13:40-13:50	No: <b><u>Michaella Goldstein</u></b> , Israel	
13:50-14:00	Discussion	
<b>14:00-14:30</b>	<b>Debate 3: Treatment of Non-exudative CNV should begin when detected on OCTA, even in the absence of fluid on traditional cross sectional OCT</b>	
14:00-14:10	Yes: <b><u>Nadia K. Waheed</u></b> , USA	
14:10-14:20	No: <b><u>Usha Chakravarthy</u></b> , UK	
14:20-14:30	Discussion	
<b>14:30-15:00</b>	<i>Visit Companies Information Corner and ePosters</i>	
<b>15:00-16:00</b>	<b>Industry-Sponsored Symposium</b>	
<b>16:00-16:15</b>	<i>Visit Companies Information Corner and ePosters</i>	



**PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)**

**VISION ACADEMY**

<b>Friday, June 24, 2022</b>		<b>Hall A</b>
<b>16:15-17:15</b>	<b>Controversies Inspired by the Vision Academy: When should anti-VEGF Therapy be stopped in AMD?</b>	
Chairs:	<b><u>Barry Kuppermann</u></b> , USA; <b><u>Anat Loewenstein</u></b> , Israel	
<b>16:15-16:20</b>	An introduction to the Vision Academy: <b><u>Barry Kuppermann</u></b> , USA	
<b>16:20-16:45</b>	<b>Debate 1: Should Anti-VEGF Therapy be stopped in cases of futility?</b>	
16:20-16:25	Yes: <b><u>David Wong</u></b> , Canada	
16:25-16:30	No: <b><u>Jean-Francois Korobelnik</u></b> , France	
16:30-16:35	Presentation of Vision Academy Recommendations: <b><u>Anat Loewenstein</u></b> , Israel	
16:35-16:45	Questions from the Audience	
<b>16:45-17:10</b>	<b>Debate 2: Should Anti-VEGF Therapy be stopped in cases of success?</b>	
16:45-16:50	Yes: <b><u>Laurent Kodjikian</u></b> , France	
16:50-16:55	No: <b><u>Martin S. Zinkernagel</u></b> , Switzerland	
16:55-17:00	Presentation of Vision Academy Recommendations: <b><u>Anat Loewenstein</u></b> , Israel	
17:00-17:10	Questions from the Audience	
<b>17:10-17:15</b>	Looking Forward with the Vision Academy: <b><u>Anat Loewenstein</u></b> , Israel	



**PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)**

**MEDICAL RETINA 2 | Diabetic Macular Edema (DME)**

Saturday, June 25, 2022		Hall A
<b>11:00-12:30</b>	<b>MEDICAL RETINA 2   Diabetic Macular Edema and Proliferative Diabetic Retinopathy</b>	
Chairs:	<b><u>Paolo Lanzetta</u></b> , Italy; <b><u>Sobha Sivaprasad</u></b> , UK; <b><u>Francesco Bandello</u></b> , Italy	
<b>11:00-11:30</b>	<b>Debate 1: Are corticosteroids effective for the management of diabetic retinopathy?</b>	
11:00-11:10	Yes: <b><u>Dinah Zur</u></b> , Israel	
11:10-11:20	No: <b><u>Richard Gale</u></b> UK	
11:20-11:30	Discussion	
<b>11:30-12:00</b>	<b>Debate 2: Is treatment of NPDR with pharmacotherapy warranted at this time?</b>	
11:30-11:40	Yes: <b><u>Sobha Sivaprasad</u></b> , UK	
11:40-11:50	No: <b><u>Susan Bressler</u></b> , USA	
11:50-12:00	Discussion	
<b>12:00-12:30</b>	<b>Debate 3: Combining VEGF and Ang2-inhibition Offers the Potential for Greater Visual Acuity and Duration Benefits for DME compared with Current Anti-VEGF Agents</b>	
12:00-12:10	Yes: <b><u>Sandrine Zweifel</u></b> , Switzerland	
12:10-12:20	No: <b><u>Patricia Udaondo</u></b> , Spain	
12:20-12:30	Discussion	
<b>12:30-13:00</b>	<i>Visit Companies Information Corner and ePosters</i>	
<b>13:00-14:00</b>	<b>Industry-Sponsored Symposium</b>	
<b>14:00-14:15</b>	<i>Visit Companies Information Corner and ePosters</i>	



**PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)**

**MEDICAL RETINA 3 | Potentially Longer Acting Strategies**

<b>Saturday, June 25, 2022</b>		<b>Hall A</b>
<b>14:15-15:45</b>	<b>MEDICAL RETINA 3   New treatment strategies</b>	
Chairs:	<u>Susan Bressler</u> , USA; <u>Patricia Udaondo</u> , Spain	
<b>14:15-14:45</b>	<b>Debate 1: Biosimilars are an important treatment option for retinal diseases</b>	
14:15-14:25	Yes: <u>Ashish Sharma</u> , India	
14:25-14:35	No: <u>Paolo Lanzetta</u> , Italy	
14:35-14:45	Discussion	
<b>14:45-15:15</b>	<b>Debate 2: Continuous delivery with the Port Delivery System should become the standard of care for patients with nAMD</b>	
14:45-14:55	Yes: <u>Peter Campochiaro</u> , USA	
14:55-15:05	No: <u>Patricia Udaondo</u> , Spain	
15:05-15:15	Discussion	
<b>15:15-15:45</b>	<b>Debate 3: Sub-retinal Viral vector gene therapy delivery of anti-VEGF is a viable management option for the management of retinal disease</b>	
15:15-15:25	Yes: <u>Arshad Khanani</u> , USA	
15:25-15:35	No: <u>Paolo Lanzetta</u> , Italy	
15:35-15:45	Discussion	
<b>15:45-16:00</b>	<b><i>Visit Companies Information Corner and ePosters</i></b>	



**PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)**

**MEDICAL RETINA 4 | AMD and Hereditary Retinal Degeneration Topics**

<b>Saturday, June 25, 2022</b>		<b>Hall A</b>
<b>16:00-17:30</b>	<b>MEDICAL RETINA 4   AMD and Hereditary Retinal Degeneration Topics</b>	
Chairs:	<b><u>Hendrik Scholl</u></b> , Switzerland; <b><u>Caroline C. Klaver</u></b> , The Netherlands	
<b>16:00-16:30</b>	<b>Debate 1: Stem cells are a viable option for the treatment of retinal degeneration</b>	
16:00-16:10	Yes: <b><u>Matias Iglicki</u></b> , Argentina	
16:10-16:20	No: <b><u>Hendrik Scholl</u></b> , Switzerland	
16:20-16:30	Discussion	
<b>16:30-17:00</b>	<b>Debate 2: Are the treatment outcomes with home OCT in neovascular AMD worth the increased cost</b>	
16:30-16:40	Yes: <b><u>Nancy Holekamp</u></b> , USA	
16:40-16:50	No: <b><u>Richard F. Spaide</u></b> , USA	
16:50-17:00	Discussion	
<b>17:00-17:30</b>	<b>Debate 3: Suprachoroidal injection of a viral vector expressing an anti-VEGF protein is a viable treatment option for the management of retinal disease</b>	
17:00-17:10	Yes: <b><u>Peter Campochiaro</u></b> , USA	
17:10-17:20	No: <b><u>William F. Mieler</u></b> , USA	
17:20-17:30	Discussion	



**PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)**

**HALL B**

**SURGICAL RETINA | NOVEL PROCEDURES AND SURGICAL SYSTEMS**

Friday, June 24, 2022		Hall B
<b>13:00-14:30</b>	<b>SURGICAL RETINA   Novel Procedures and Surgical Systems</b>	
Chairs:	<u>William F. Mieler</u> , USA; <u>Stanislao Rizzo</u> , Italy, <u>Stratos Gotzardis</u> , Greece,	
<b>13:00-13:30</b>	<b>Debate 1: Vitrectomy is safe and beneficial in the management of significant vitreous opacities</b>	
13:00-13:10	Yes: <u>Francesco Boscia</u> , Italy	
13:10-13:20	No: <u>William F. Mieler</u> , USA	
13:20-13:30	Discussion	
<b>13:30-14:00</b>	<b>Debate 2: Digital, heads up imaging in the operating room has led to improvement in surgical outcomes</b>	
13:30-13:40	Yes: <u>Stanislao Rizzo</u> , Italy	
13:40-13:50	No: <u>Elad Moisseiev</u> , Israel	
13:50-14:00	Discussion	
<b>14:00-14:30</b>	<b>Debate 3: The best treatment for a 45 year old, 3 diopter myope with a single superior retina tear in a Macula off RD without PVR is a sclera buckle</b>	
14:00-14:10	Yes: <u>Taiji Sakamoto</u> , Japan	
14:10-14:20	No: <u>Christina Weng</u> , USA	
14:20-14:30	Discussion	
<b>14:30-15:00</b>	<i>Visit Companies Information Corner and ePosters</i>	



**PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)**

**NEURO-OPHTHALMOLOGY 1 | The Afferent Pathway**

<b>Saturday, June 25, 2022</b>		<b>Hall B</b>
<b>11:00-12:30</b>	<b>NEURO-OPHTHALMOLOGY 1   The Afferent Pathway</b>	
Chairs:	<b>Andrew G. Lee, USA; Prem S. Subramanian, USA</b>	
<b>11:00-11:30</b>	<b>Debate 1: Should patients with thyroid eye disease and clinical activity score (CAS) of &gt;3 be offered teprotumumab?</b>	
11:00-11:10	Yes: <b>Prem S. Subramanian, USA</b>	
11:10-11:20	No: <b>John Chen, USA</b>	
11:20-11:30	Discussion	
<b>11:30-12:00</b>	<b>Debate 2: Should patients with giant cell arteritis be offered tocilizumab after steroids?</b>	
11:30-11:40	Yes: <b>John Chen, USA</b>	
11:40-11:50	No: <b>Prem S. Subramanian, USA</b>	
11:50-12:00	Discussion	
<b>12:00-12:30</b>	<b>Case Presentations</b>	
	Moderator: <b>John Chen, USA</b>	
	Panelists: <i>All Speakers</i>	
	<b>Andrew G. Lee, USA; Prem S. Subramanian, USA; Fiona Costello, Canada</b>	
	<ol style="list-style-type: none"> <li>1. Series of elderly patients with acute onset diplopia</li> <li>2. 57yo male with diplopia and ptosis</li> <li>3. 70yo male with progressive worsening diplopia</li> <li>4. 45yo male with funny eye movements</li> <li>5. 43yo male in the ICU with funny eye movements</li> </ol>	
<b>12:30-13:00</b>	<b>Visit Companies Information Corner and ePosters</b>	





**PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)**

**UVEITIS**

Saturday, June 25, 2022		Hall B
<b>14:15-15:45</b>	<b>UVEITIS</b>	
Chairs:	<b><u>Bahram Bodaghi</u></b> , France; <b><u>Zohar Habot-Wilner</u></b> , Israel	
<b>14:15-14:45</b>	<b>Debate 1: Intravitreal Corticosteroids for the Treatment of Uveitic Macular Edema is Better (or Similar) than Systemic Treatment</b>	
14:15-14:25	Yes: <b><u>Piergiorgio Neri</u></b> , UAE/USA	
14:25-14:35	No: <b><u>Bahram Bodaghi</u></b> , France	
14:35-14:45	Discussion	
<b>14:45-15:15</b>	<b>Debate 2: Intravenous Treatments are Mandatory in Acute Retinal Necrosis Syndrome</b>	
14:45-14:55	Yes: <b><u>Bahram Bodaghi</u></b> , France	
14:55-15:05	No: <b><u>Zohar Habot-Wilner</u></b> , Israel	
15:05-15:15	Discussion	
<b>15:15-15:45</b>	<b>Debate 3: Ocular imaging should be used for the diagnosis of anterior scleritis</b>	
15:15-15:25	Yes: <b><u>Zohar Habot-Wilner</u></b> , Israel	
15:25-15:35	No: <b><u>Marion Munk</u></b> , Switzerland	
15:35-15:45	Discussion	
<b>15:45-16:00</b>	<b><i>Visit Companies Information Corner and ePosters</i></b>	



**PROGRAM TIMES REFER TO CENTRAL EUROPEAN TIME (CET)**

**NEURO-OPHTHALMOLOGY 2 | The Efferent Pathway and Systemic Disorders**

Saturday, June 25, 2022		Hall B
<b>16:00-17:30</b>	<b>NEURO-OPHTHALMOLOGY 2   The Efferent Pathway and Systemic Disorders</b>	
Chairs:	<b><u>Andrew G. Lee</u></b> , USA; <b><u>Prem S. Subramanian</u></b> , USA	
<b>16:00-16:30</b>	<b>Debate 1: Should patients with NMO be offered eculizumab?</b>	
16:00-16:10	Yes: <b><u>Fiona Costello</u></b> , Canada	
16:10-16:20	No: <b><u>Andrew G. Lee</u></b> , USA	
16:20-16:30	Discussion	
<b>16:30-17:00</b>	<b>Debate 2: Should all patients with optic neuritis have both NMO and MOG testing?</b>	
16:30-16:40	Yes: <b><u>John Chen</u></b> , USA	
16:40-16:50	No: <b><u>Andrew G. Lee</u></b> , USA	
16:50-17:00	Discussion	
<b>17:00-17:30</b>	<b>Case Presentations</b>	
	Moderator: <b><u>John Chen</u></b> , USA	
	Panelists: <i>All Speakers</i>	
	<b><u>Andrew G. Lee</u></b> , USA; <b><u>Prem S. Subramanian</u></b> , USA; <b><u>Fiona Costello</u></b> , Canada	
	<ol style="list-style-type: none"> <li>1. 34yo female with unilateral vision loss and eye pain</li> <li>2. 48yo male with bilateral vision loss and disc edema</li> <li>3. 23yo female with bilateral disc edema and headaches</li> <li>4. 67yo male with acute painless unilateral vision loss</li> </ol>	